Recruitment

Recruitment Status
Completed

Inclusion Criterias

Generally healthy postmenopausal women, aged 40-64. Intact Uterus
Generally healthy postmenopausal women, aged 40-64. Intact Uterus

Exclusion Criterias

The use of oral, vaginal, or transdermal estrogen, androgen or progestin-containing medications within 30 days before study drug administration.
The use of oral, vaginal, or transdermal estrogen, androgen or progestin-containing medications within 30 days before study drug administration.

Summary

Conditions
Healthy
Type
Interventional
Phase
Phase 1
Design
  • Allocation: Non-Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Basic Science

Participation Requirements

Age
Between 40 years and 64 years
Gender
Only females

Inclusion Criterias

Generally healthy postmenopausal women, aged 40-64. Intact Uterus
Generally healthy postmenopausal women, aged 40-64. Intact Uterus

Exclusion Criterias

The use of oral, vaginal, or transdermal estrogen, androgen or progestin-containing medications within 30 days before study drug administration.
The use of oral, vaginal, or transdermal estrogen, androgen or progestin-containing medications within 30 days before study drug administration.

Locations

Miami, Florida, 33125
Miami, Florida, 33126
Miami, Florida, 33125
Miami, Florida, 33126

Tracking Information

NCT #
NCT02100553
Collaborators
Not Provided
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer